Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections.

Abstract

The acyclic nucleoside phosphonates [HPMPC: cidofovir, Vistide; PMEA: adefovir dipivoxil, Hepsera; and PMPA: tenofovir, Viread] have proven to be effective in vitro (cell culture systems) and in vivo (animal models and clinical studies) against a wide variety of DNA virus and retrovirus infections, for example, cidofovir against herpesvirus [herpes simplex virus type 1 and 2, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus type 6, 7 and 8), polyoma-, papilloma-, adeno- and poxvirus (variola virus, cowpox virus, vaccinia virus, molluscum contagiosum virus and orf) infections; adefovir against herpesvirus, hepadnavirus [human hepatitis B virus] and retrovirus [HIV type-1 and 2, simian immunodeficiency virus and feline immunodeficiency virus] infections; and tenofovir against both hepadna- and retrovirus infections. Cidofovir has been officially approved for the treatment of cytomegalovirus retinitis in AIDS patients, tenofovir disoproxil fumarate (Viread) for the treatment of HIV infections (i.e., AIDS) and adefovir dipivoxil for the treatment of chronic hepatitis B.

• Authors: Eric De Clercq
• Journal: Expert review of anti-infective therapy (Expert Rev Anti Infect Ther) Vol. 1 Issue 1 Pg. 21-43 (Jun 2003) ISSN: 1478-7210 [Print] England
• PMID: 15482100 (Publication Type: Journal Article, Review)

Chemical References

• Antiviral Agents
• Organophosphonates
• Organophosphorus Compounds
• Cytosine
• Tenofovir
• Adenine
• Cidofovir
• adefovir dipivoxil

Topics

• Adenine (analogs & derivatives, therapeutic use)
• Animals
• Antiviral Agents (therapeutic use)
• Cidofovir
• Cytosine (analogs & derivatives, therapeutic use)
• DNA Virus Infections (drug therapy)
• Disease Models, Animal
• Drug Resistance, Viral
• Humans
• Organophosphonates
• Organophosphorus Compounds (therapeutic use)
• Retroviridae Infections (drug therapy)
• Tenofovir